Company intelligence / Profile preview

VisionGate

Phoenix, Arizona, United Statesvisiongate3d.com ↗

Ownership: Private
Development stage: Other

Overview

VisionGate’s lead product, the LuCED® Lung Test, uses non-invasive sputum samples analyzed by the proprietary Cell-CT™ 3D imaging platform with AI to detect abnormal cells indicative of early-stage lung cancer or bronchial dysplasia. The technology has demonstrated high accuracy in cell classification but specific clinical trial results are not publicly detailed as of June 2025[1][2][4][5].

Therapeutic areas: PulmonologyOncology
Modalities: DeviceDiagnostic test (liquid biopsy)AI-powered diagnostic platform
Industry: Pathology

Beyond the preview

Go deeper on VisionGate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VisionGate.

Explore the full profile